Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.
In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine have shed new light on the location and function of power-generating waves on cancer cell membranes. The scientists say the waves, generated by rhythmic propagation of enzymes that produce energy from glucose, could potentially be used to better stage cancers and as targets for new cancer drugs.
Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma resist thermal ablation and even thrive after being treated with high heat, according to a study from investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Certain cardiac blood markers can strongly predict future cancer risk—even in people with no history or symptoms of heart disease, according to a UCLA Health study.
Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement.
The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.
The U.S. House of Representatives Thursday passed President Trump’s “One Big Beautiful Bill,” a sweeping legislation that makes the biggest cuts to Medicaid since the program began in the 1960s.
Researchers funded by NIH will now be required to make their scientific papers available to read for free as soon as they are published in a peer-reviewed journal.
NIH Director Jay Bhattacharya has started his own podcast called “The Director’s Desk,” where, according to the description on YouTube, he plans to host weekly conversations on scientific careers, leadership, and innovation at NIH.
Breast medical oncologist and cancer survivorship expert Neil M. Iyengar was appointed director of survivorship services at Winship Cancer Institute of Emory University.
